Evidence map›Paper›PMID 41527139›Full record

ArticleBiology direct2026

S100A4 triggeres the pyroptosis of vsmcs: association with mitochondrial damage, impaired mitophagy, and Ca

Junjie Huang, Binbin Zhou, Lie Wang, Qingjin Huang, Xiaowen Lin, Hu Zhao, Yin Xia

Abstract read
In one paragraph

Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Junjie HuangGuangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, 519000, China.
Binbin ZhouDepartment of Emergency Medicine, 900th Hospital of the Joint Logistics Support Force, Fuzhou, Fujian, 350025, China.
Lie WangDepartment of General Surgery, 900th Hospital of the Joint Logistics Support Force, Fuzhou, Fujian, 350025, China.
Qingjin HuangDepartment of Vascular Surgery, The Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine, 602, Middle 817 Road, Taijiang District, Fuzhou, Fujian, 350004, China.
Xiaowen LinDepartment of Vascular Surgery, The Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine, 602, Middle 817 Road, Taijiang District, Fuzhou, Fujian, 350004, China.
Hu ZhaoDepartment of General Surgery, 900th Hospital of the Joint Logistics Support Force, Fuzhou, Fujian, 350025, China. zhaohubear@163.com.
Yin XiaDepartment of Vascular Surgery, The Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine, 602, Middle 817 Road, Taijiang District, Fuzhou, Fujian, 350004, China. xiayin@fjtcm.edu.cn.

Funding

Joint Funds for the Innovation of Science and Technology, Fujian province, China 2024Y9498
6 · The paper itself

Abstract

backgroundAtherosclerotic occlusive disease of the lower extremities (ASO-LE) is associated with high rates of disability and mortality, and even after surgery, the rate of long-term lumen patency remains low. Vascular smooth muscle cells (VSMCs) are key players in atherosclerosis. The aim of this study was to investigate the action of S100 calcium-binding protein A4 (S100A4) in regulating VSMCs in ASO-LE.

resultsThe overexpression of S100A4 in the vessel wall of ASO-LE is detected, and the expression of markers of pyroptosis is high. S100A4 causes mitochondrial damage in VSMCs, increases the intracellular ROS and MDA levels, and decreases the level of SOD, which result in oxidative stress. Moreover, S100A4 disrupts the mitophagy process, manifested by inhibited LC3-II conversion and reduced PE levels, suggesting that the lipidation step of LC3 may be disrupted. These promot the accumulation of a large amount of damaged mitochondria with insufficient clearance and activate intracellular AIM2 inflammatory vesicles, which mediate the occurrence of pyroptosis. We also find that the functions of S100A4 may be associated with disturbances in intracellular calcium ion (Ca2+) signaling, both S100A4 transcription inhibitor (niclosamide) and calcium channel blockers can inhibit the above damaging effects.

conclusionsS100A4 plays a crucial role in the progression of ASO-LE by driving mitochondrial damage and impairing mitophagy in vascular smooth muscle cells, and it is a potential existing strategies for blocking chronic inflammation that may be used to treat lower extremity atherosclerotic occlusion. CLINICAL TRIAL NUMBER: Not applicable.

Indexed as

CalciumMitochondriaMitophagyMuscle, Smooth, VascularMyocytes, Smooth MusclePyroptosisS100 Calcium-Binding Protein A4AnimalsAtherosclerosisRatsCalciumS100 Calcium-Binding Protein A4AtherosclerosisMitophagyPyroptosisS100A4Vascular smooth muscle cells

Identifiers

PMID41527139
PMCPMC12888506

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.